======= GLRX3 =======
== Gene Information ==
* **Official Symbol**: GLRX3
* **Official Name**: glutaredoxin 3
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10539|10539]]
* **UniProt**: [[https://www.uniprot.org/uniprot/O76003|O76003]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=GLRX3&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20GLRX3|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/612754|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a member of the glutaredoxin family. Glutaredoxins are oxidoreductase enzymes that reduce a variety of substrates using glutathione as a cofactor. The encoded protein binds to and modulates the function of protein kinase C theta. The encoded protein may also inhibit apoptosis and play a role in cellular growth, and the expression of this gene may be a marker for cancer. Pseudogenes of this gene are located on the short arm of chromosomes 6 and 9. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Dec 2010].
* **UniProt Summary**: Together with BOLA2, acts as a cytosolic iron-sulfur (Fe-S) cluster assembly factor that facilitates [2Fe-2S] cluster insertion into a subset of cytosolic proteins (PubMed:26613676, PubMed:27519415). Acts as a critical negative regulator of cardiac hypertrophy and a positive inotropic regulator (By similarity). Required for hemoglobin maturation (PubMed:23615448). Does not possess any thyoredoxin activity since it lacks the conserved motif that is essential for catalytic activity. {ECO:0000250|UniProtKB:Q9CQM9, ECO:0000269|PubMed:23615448, ECO:0000269|PubMed:26613676, ECO:0000269|PubMed:27519415}.
|Glutaredoxin|
|Thioredoxin|
|DIM1|
|Phosducin|
|[2Fe-2S] cluster assembly|
|glutathione disulfide oxidoreductase activity|
|iron-sulfur cluster binding|
|protein maturation by iron-sulfur cluster transfer|
|iron-sulfur cluster assembly|
|metallo-sulfur cluster assembly|
|protein disulfide oxidoreductase activity|
|negative regulation of cardiac muscle hypertrophy|
|regulation of the force of heart contraction|
|negative regulation of muscle hypertrophy|
|protein kinase C binding|
|regulation of cardiac muscle hypertrophy|
|regulation of muscle hypertrophy|
|cellular iron ion homeostasis|
|cell redox homeostasis|
|electron transfer activity|
|iron ion homeostasis|
|regulation of muscle adaptation|
|cellular transition metal ion homeostasis|
|transition metal ion homeostasis|
|Z disc|
|cell cortex|
|electron transport chain|
|cofactor biosynthetic process|
|protein maturation|
|regulation of muscle system process|
|regulation of heart contraction|
|regulation of blood circulation|
|sulfur compound metabolic process|
|dendrite|
|generation of precursor metabolites and energy|
|cofactor metabolic process|
|cellular metal ion homeostasis|
|regulation of system process|
|metal ion homeostasis|
|cellular cation homeostasis|
|cellular ion homeostasis|
|cation homeostasis|
|inorganic ion homeostasis|
|cellular chemical homeostasis|
|ion homeostasis|
|cellular homeostasis|
|oxidation-reduction process|
|identical protein binding|
|chemical homeostasis|
|negative regulation of multicellular organismal process|
|RNA binding|
|homeostatic process|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-3.12|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-2.7|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-2.66|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-2.56|
|[[:results:exp147|Resveratrol 16μM R03 exp147]]|-2.26|
|[[:results:exp180|Dynasore 10μM R04 exp180]]|-2.21|
|[[:results:exp436|Dynasore 7μM R08 exp436]]|-2.21|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.17|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.14|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.13|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-2.08|
|[[:results:exp517|Quercetin 20μM R08 exp517]]|-2.07|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-1.95|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|-1.89|
|[[:results:exp363|GSK-J4 1-1.25μM to day4 R07 exp363]]|-1.88|
|[[:results:exp472|CI-1040 9.5μM R08 exp472]]|-1.87|
|[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-1.79|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.76|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|-1.73|
|[[:results:exp450|Artemisinin 50μM R08 exp450]]|-1.7|
|[[:results:exp447|Amiloride 100μM R08 exp447]]|1.72|
|[[:results:exp209|Deguelin 0.15μM R05 exp209]]|1.8|
|[[:results:exp230|Epigallocatechin gallate 20μM R05 exp230]]|1.85|
|[[:results:exp465|Cannabidiol 13μM R08 exp465]]|1.92|
|[[:results:exp519|RS-1 10μM R08 exp519]]|1.98|
|[[:results:exp191|Hypoxia 5%O2 R04 exp191]]|2.02|
|[[:results:exp248|UM0131023 0.05μM R05 exp248]]|2.02|
|[[:results:exp495|IWR1 50μM R08 exp495]]|2.38|
^Gene^Correlation^
|[[:human genes:f:fam96b|FAM96B]]|0.481|
|[[:human genes:s:slc11a2|SLC11A2]]|0.414|
Global Fraction of Cell Lines Where Essential: 36/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|6/26|
|breast|1/33|
|central nervous system|4/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|1/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|1/21|
|liver|1/20|
|lung|3/75|
|lymphocyte|1/16|
|ovary|3/26|
|pancreas|0/24|
|peripheral nervous system|1/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|2/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|1/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 8244
* **Expression level (log2 read counts)**: 6.29
{{:chemogenomics:nalm6 dist.png?nolink |}}